Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients

Lorena Lerner1, Teresa G. Hayes2,3, Nianjun Tao1, Brian Krieger1, Bin Feng1, Zhenhua Wu1, Richard Nicoletti1, M. Isabel Chiu1, Jeno Gyuris1 & Jose M. Garcia2,3,4*

1AVEO Pharmaceuticals, Cambridge, MA, USA; 2Department of Medicine, Center for Translational Research on Inflammatory Diseases (CTRID), Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA; 3Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA; 4Department of Molecular and Cell Biology and Huffington Center on Aging, Baylor College of Medicine, Houston, TX, USA.

Abstract

Background Cancer-related weight loss is associated with increased inflammation and decreased survival. The novel inflammatory mediator growth differentiation factor (GDF)15 is associated with poor prognosis in cancer but its role in cancer-related weight loss (C-WL) remains unclear. Our objective was to measure GDF15 in plasma samples of cancer subjects and controls and establish its association with other inflammatory markers and clinical outcomes.

Methods We measured body weight, appetite, plasma GDF15, and other inflammatory markers in men with cancer-related weight loss (C-WL, n = 58), weight stable patients with cancer (C-WS, n = 72), and non-cancer controls (Co, n = 59) matched by age and pre-illness body mass index. In a subset of patients we also measured handgrip strength, appendicular lean body mass (aLBM), Eastern Cooperative Oncology Group (ECOG), and Karnofsky performance scores.

Results GDF15, interleukin (IL)-6 and IL-8 were increased in C-WL versus other groups. IL-1 receptor antagonist, IL-4, interferon–gamma, tumour necrosis factor alpha, and vascular endothelial growth factor A were increased in C-WL versus C-WS, and Activin A was significantly downregulated in Co versus other groups. C-WL patients had lower handgrip strength, aLBM, and fat mass, and Eastern Cooperative Oncology Group and Karnofsky performance scores were lower in both cancer groups. GDF15, IL-6, and IL-8 significantly correlated with weight loss; GDF15 negatively correlated with aLBM, handgrip strength, and fat mass. IL-8 and Activin A negatively correlated with aLBM and fat mass. GDF15 and IL-8 predicted survival adjusting for stage and weight change (Cox regression \( P < 0.001 \) for both).

Conclusion GDF15 and other inflammatory markers are associated with weight loss, decreased aLBM and strength, and poor survival in patients with cancer. GDF15 may serve as a prognostic indicator in cancer patients and is being evaluated as a potential therapeutic target for cancer-related weight loss.

Keywords GDF15; Inflammation; Cachexia; MIC-1; Cytokines; IL-6; IL-8; Activin A

Received: 7 October 2014; Revised: 24 February 2015; Accepted: 16 March 2015

*Correspondence to: Jose M. Garcia, MD, PhD, Div. of Endocrinology, Diabetes and Metabolism, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd, Bldg 109, Rm 210, Houston, TX 77030, USA.: Tel: (713)794-7989, Fax: (713)794-7771, Email: jgarcia1@bcm.edu

Introduction

Over 1.5 million individuals in the USA are diagnosed with cancer each year. Energy metabolism is usually affected in this population, leading to an involuntary decrease in body weight because of fat and muscle loss known as cachexia. This condition eventually is present in up to 80% of patients with advanced cancer and is associated with decreased response to therapy, quality of life, and survival.1–3 Weight loss related to cancer has been associated with increased inflammation. Moreover, inflammation has been directly implicated in all components of cachexia including weight loss, decreased food intake, increased muscle proteolysis, increased adipose tissue lipolysis, and energy expenditure.4–6

The novel inflammatory marker growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine-1, is a cytokine member of the transforming growth factor beta family. This factor circulates in plasma at
detectable concentrations in healthy individuals but is significantly elevated in cancer. More recently, it has been postulated to play a role in the development of cancer-related weight loss (C-WL). In animal models, GDF15 was shown to induce anorexia, fat, and lean body mass loss. While its role in human cancer is not yet understood, some but not all studies report an association between GDF15 levels and weight loss and poor prognosis and decreased survival.

There is an ongoing search for anabolic, catabolic, and anti-catabolic circulating biomarkers that would aid in establishing the diagnosis and prognosis in patients at risk or with ongoing C-WL. In this study, we aim at determining the association, if any, between circulating levels of a panel of cytokines, including GDF15, with body weight, lean and fat mass (FM), muscle strength, performance status, and survival in a cross-sectional study of patients with cancer and with and without weight loss and a non-cancer control group.

Materials and methods

Study design

This study was performed at the Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston, TX. The protocol was approved by the Institutional Review Boards of Baylor College of Medicine and MEDVAMC. Patients were recruited from November 2006 to August 2010 from the MEDVAMC. All clinical investigations were conducted in accordance with the guidelines in The Declaration of Helsinki. This was a cross-sectional study of male patients with cancer with and without significant weight loss (greater than 5% over the previous 6 months), and male non-cancer controls matched by age and body mass index to the two cancer groups. The study also had a retrospective follow-up component when information was gathered from the electronic medical records to collect survival data. Subjects were followed until November 2011 or until death, whichever occurred first (median: 1485 days). The Social Security Death Index and medical record were used to enter date of death.

Eligibility criteria

Subjects were ≥18 years old and provided written informed consent. The study included (1) individuals with cancer, excluding non-melanoma skin cancer and cancer-related weight loss (C-WL, n = 58); (2) individuals with cancer, excluding non-melanoma skin cancer, without weight loss [cancer-weight stable (C-WS), n = 72]; and (3) weight-stable subjects without cancer (controls, Co, n = 59). Exclusion criteria included Eastern Cooperative Oncology Group (ECOG) score >2, body mass index >35 (because of a weight limitation of the dual-energy x-ray absorptiometry scanner), history of congestive heart failure, active infections, or other inflammatory conditions associated with weight loss, evidence of ascites or clinically significant oedema, use of anabolic agents, appetite stimulants (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), alcohol abuse, tube feeding or parenteral nutrition in the prior three months, participation in a clinical trial with investigational agents within one month prior to recruitment, and use of androgens or anti-androgens. None of the cancer subjects were receiving curative chemotherapy.

Study measures

Body weight changes were assessed using weights recorded in the electronic medical records 12 months before enrolment (baseline), 6 months before enrolment, or at the time of enrolment in the study. Subjects were weighed on a calibrated scale, and appetite was assessed by the previously validated Anderson Symptom Assessment Scale visual analogue scale.

In a subset of subjects (34 C-WL, 36 C-WS and 40 Co), the following outcomes were also measured: Functional assessment was performed by previously validated ECOG, Karnofsky performance scale (KPS), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaires. All questionnaires except ECOG were adjusted during data analysis so that the lowest number meant worst symptoms and the highest number meant no symptoms at all. Lean body mass (LBM) and FM were measured by dual-energy x-ray absorptiometry (Lunar Prodigy DF+14333, Software 6.7v, GE). Grip strength was assessed with a hand-held dynamometer (Jamar Hydraulic Dynamometer, model #5030J1, J.A. Preston Corp., Clifton, NJ, USA). Some of these results have been reported previously.

The following markers were measured in an early morning fasting plasma samples: Activin A, eotaxin, fibroblast growth factor basic (FGFb), granulocyte-colony stimulating factor (G-CSF), GDF15, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma, interleukin (IL)-10, IL-12p70, IL-13, IL-15, IL-17, IL-1β, IL-1 receptor a (IL-1Ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, interferon gamma-induced protein 10 (IP-10 or CXCL10), monocyte chemotactic protein 1 (MCP-1 or CCL2), macrophage inflammatory protein-1 alpha (MIP-1α or CCL3), macrophage inflammatory protein-1 beta (MIP-1β or CCL4), platelet-derived growth factor B (PDGF-bb), regulated on activation, normal T cell expressed and secreted (RANTES or CCL5), tumour necrosis factor alpha (TNF-α), and vascular endothelial growth factor A (VEGFA). Individual enzyme-linked immunosorbent assay kits were used for measurements of GDF15 and Activin A (R&D Systems, Minneapolis, MN, USA). The rest of the cytokines were measured using Bio-Plex Pro™ Human Cytokine 27-Plex Assay from Bio-Rad® (Luminex®, magnetic beads, Bio-Rad, Hercules, CA, USA) and analysed by using the Bio-Plex Manager 2.0 software (all from Bio-Rad Laboratories). Albumin and highly
sensitive C-reactive protein (hs-CRP) were also measured as we previously published.\textsuperscript{15} All procedures were carried out according to the manufacturer’s instructions. Because no normal values have been established for these analytes and our sample is too small to establish such values, information is presented using mean ± SD or SEM or quartiles.

### Statistical analysis

SPSS v17.00 (SPSS Inc., Chicago, IL, USA) and R v2.14.1 (http://www.r-project.org/) were used for statistical analysis. Variables were summarized descriptively by group using N, mean and standard error for normally distributed continuous variables, by median and interquartile range for non-normally distributed variables, and by frequencies (%) for nominal or ordinal variables. A three-group (controls vs C-WL vs C-WS) analysis of variance was used to analyse normally distributed variables, and by frequencies (%) for nominal or ordinal variables. A three-group (controls vs C-WL vs C-WS) analysis of variance was used to analyse normally distributed continuous variables, and non-parametric tests were used for variables non-normally distributed. Data from analytes were converted to categorical variables (detectable vs non-detectable) when more than 25% of samples were below the level of detection for the assay (eotaxin, G-CSF, GM-CSF, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-1, and MIP-1α). Statistical comparisons for these categorical variables were performed using the chi-squared test. For multiple comparisons, the Dunn’s test was used. \( P \) values ≤0.05 were considered statistically significant. It was anticipated that cancer stage may be highly associated with C-WL and survival. The association between GDF15 and other cytokines and C-WL and survival was measured by a logistic regression model or Cox proportional hazards model to determine which variables, in addition to cancer stage, were significant predictors of C-WL and mortality. The measure of association was given by the \( P \) value. Pearson’s correlations, or non-parametric Spearman’s correlation when the data were not normally distributed, were obtained between continuous variables. See supplemental data for more information.

### Results

Subjects were all male with similar body weights 12 months prior to enrolment (%). Subjects in the C-WS group were slightly older than in the other two groups, although this was probably not clinically relevant. As expected, C-WL subjects had significantly lower body weight and had experienced a significant degree of weight loss over the previous 6 and 12 months compared with non-cancer controls and to subjects with cancer and without weight loss (Table 1). There were no significant differences in ethnicity or rate of comorbidities between groups but controls had a lower rate of exposure to opioids compared with the other groups, as expected. There were no significant differences regarding diagnosis, stage, opioid, or chemotherapy use between the

| Table 1 Baseline characteristics |
|----------------------------------|
| Characteristics                  | Controls | Cancer weight stable | Cancer weight loss | \( P \) value |
| No. of subjects                  | 59       | 72                   | 58               | 0.025 |
| Age in years                     | 63.2     | 66.8 £               | 63.1             | 0.21  |
| Race (n (%))                     |          |                      |                  |       |
| Caucasian                        | 38 (64)  | 50 (69)              | 45 (78)          |       |
| African American                 | 14 (24)  | 14 (19)              | 12 (21)          |       |
| Hispanic                         | 7 (12)   | 6 (8)                | 1 (2)            |       |
| Asian                            | 2 (3)    |                      |                  |       |
| Body weight 12 months before enrolment (kg) | 91.4 | 87.8 | 89.7 | 0.37 |
| Enrolment body weight (kg)       | 13       |                      |                  |       |
| Mean                             | 90.9**   | 87.1 **              | 78.2             | <0.001|
| SD                              | 12.6     | 15.3                 | 13.6             | <0.001|
| Weight change 6 months prior to enrolment (%) | –0.38 ** | 0.31 **–11.7 |       | <0.001|
| SD                              | 3.1      | 4.2                  | 7.3              |       |
| Weight change 12 months prior to enrolment (%) | –0.41 ** | –0.99 **–12.5 |       |       |
| SD                              | 4.1      | 4.9                  | 7.1              |       |
| Comorbidities (n (%))            |          |                      |                  |       |
| Diabetes                         | 13 (22)  | 24 (33)              | 11 (19)          | 0.19  |
| COPD                             | 3 (5)    | 4 (6)                | 8 (14)           | 0.19  |
| Opioid use (n (%))               | 2 (3) £  | 12 (18)              | 18 (31)          | 0.002 |
| Cancer type (n (%))              |          |                      |                  | 0.2   |
| Lung                             | 20 (28)  | 21 (36)              |                  |       |
| GI                               | 13 (18)  | 14 (24)              |                  |       |
| GU                               | 16 (22)  | 6 (10)               |                  |       |
| Head and neck                    | 1 (1)    | 3 (5)                |                  |       |
| Other                            | 22 (31)  | 14 (25)              |                  |       |
| Stage (n (%))                    |          |                      |                  |       |
| I                                | 12 (17)  | 2 (3)                |                  | 0.06  |
| II                               | 10 (14)  | 13 (22)              |                  |       |
| III                              | 19 (26)  | 18 (31)              |                  |       |
| IV                               | 24 (33)  | 23 (40)              |                  |       |
| Chemotherapy regimen (n (%))     |          |                      |                  | 0.57  |
| Platinum-based                   | 16 (22)  | 17 (29)              |                  |       |
| Taxanes                          | 7 (10)   | 6 (10)               |                  |       |
| 5-Fluorouracil                   | 9 (13)   | 11 (19)              |                  |       |
| Doxorubicin                      | 2 (3)    | 2 (3)                |                  |       |
| Tyrosine kinase inhibitor        | 4 (6)    | 3 (5)                |                  |       |
| aLBM (kg)                        |          |                      |                  |       |
| Mean                             | 18.5*    | 17.6                 | 16.2             |       |
| SD                              | 2.89     | 3.3                  | 3.2              |       |
| FM (kg)                          |          |                      |                  | <0.001|
| Mean                             | 29.9**   | 25.9                 | 21.6             |       |
| SD                              | 7.22     | 7.7                  | 7.45             |       |
| HGS (kg)                         |          |                      |                  | 0.04  |
| Mean                             | 140      | 151*                 | 115              |       |
| SD                              | 68       | 45                   | 65               |       |
| ASAS appetite (1–10)             |          |                      |                  | 0.32  |
| Mean                             | 5.72     | 5.7                  | 5.23             |       |
| SD                              | 1.45     | 1.72                 | 2.51             |       |

* \( P \) < 0.05 compared with C-WL; £ \( P \) < 0.05 compared with other groups. ** \( P \) < 0.001 compared with C-WL; \( P \) < 0.001 compared with controls. IStaging performed only for solid tumours. COPD, chronic obstructive pulmonary disease; GI, gastrointestinal tumours; GU, genito-urinary tumours; aLBM, appendicular lean body mass; FM, fat mass; HGS, handgrip strength; and ASAS, Anderson symptoms assessment scale.

Journal of Cachexia, Sarcopenia and Muscle 2015; 6: 317–324

DOI: 10.1002/jcsm.12033
two cancer groups, although C-WL subjects trended to have more advanced stage disease. Analysis in a subset of patients showed that C-WL subjects had lower grip strength, aLBM, FM, and appetite scores compared with the other groups, although differences were not significant for the latter variable, as we have described previously. Also, and as previously described, weight losing when compared with weight stable cancer patients and non-cancer controls had lower albumin (3.4 ± 0.1, 3.8 ± 0.07 and 3.9 ± 0.04 g/dL, respectively, \( P < 0.001 \)) and higher hs-CRP levels (3.5 ± 1.1, 1.76 ± 0.8 and 0.49 ± 0.1 mg/dL, respectively \( P < 0.03 \)).

**GDF15 and other inflammatory markers are increased in cancer-related weight loss**

Levels of GDF15, IL-6, and IL-8 were significantly increased in C-WL versus other groups (Figure 1). Activin A was significantly elevated in both cancer groups compared with controls. IL-1Ra, IL-4, INF γ, TNFα, and VEGFA were also elevated in C-WL, but the difference only reached significance when compared with C-WS. Among the inflammatory cytokines whose presence was not detectable in more than a quarter of the samples tested, IL-10, IL-12p70, and IL-17 were significantly elevated in C-WL compared with the two other groups (Table 2). Other cytokine pairs with significant differences were also noted: increased G-CSF in C-WS versus other groups, increased IL-7 in C-WL versus C-WS, and increased MIP-1α in C-WL versus Co. There were no significant differences between groups in eotaxin, fibroblast growth factor basic, GM-CSF, IL-13, IL-15, IL-1β, IL-2, IL-5, IL-9, IP-10, MCP-1, MIP-1β, PDGFβb, and RANTES levels (data not shown). Exposure to radiation therapy has been associated with acute (4 h after exposure) elevations in GDF15 mRNA levels. In our cohort, only one subject in the cancer-weight stable group was receiving radiation therapy at the time of enrolment, although it had not been exposed to radiation 24 h before enrolment; 48 other subjects had a history of past exposure (more than 1 month before enrolment) to radiation therapy. Moreover, there was no difference in GDF15 levels or in other cytokine levels between subjects exposed and those unexposed to radiation therapy (data not shown).

![Figure 1](image-url)

**Figure 1** Upregulated cytokine levels in weight losing patients with cancer. Data are represented as box plots (median and quartiles). Circulating levels of cytokines in control patients (Co), weight stable cancer patients (C-WS), and weight losing cancer patients (C-WL). Non-parametric one-way ANOVA Kruskal–Wallis test and multiple comparisons test Dunn’s \*\( P < 0.05 \), \**\( P < 0.01 \), \***\( P < 0.001 \).

### Table 2 Increased presence of inflammatory cytokines in weight losing cancer patients

| Cytokine | Co (% of samples detected) | C-WS (% of samples detected) | C-WL (% of samples detected) |
|----------|----------------------------|------------------------------|------------------------------|
| IL-10    | 25                         | 26                           | 45**                         |
| IL-12p70 | 56                         | 53                           | 76***                        |
| IL-17    | 47                         | 46                           | 67***                        |
| MIP-1α   | 12                         | 17                           | 29**                         |
| IL-7     | 39                         | 31                           | 57***                        |
| G-CSF    | 49                         | 75*                          | 69***                        |

Chi-square test.

\*\( P < 0.01 \) compared Co to C-WS.

\**\( P < 0.05 \) compared Co to C-WL.

\***\( P < 0.05 \) compared C-WS to C-WL.

\****\( P < 0.01 \) compared C-WS to C-WL.

### Table 3 Correlations between inflammatory markers and clinical measures

|                      | aLBM       | Fat Mass   | Grip     |
|----------------------|------------|------------|----------|
| **GDF15**            | \(-0.34 (p < 0.001)\) | \(-0.25 (p = 0.012)\) | \(-0.29 (p = 0.003)\) |
| **IL-8**             | \(-0.27 (p = 0.006)\) | \(-0.30 (p = 0.002)\) | \(-0.17 (p = 0.075)\) |
| **Activin A**        | \(-0.30 (p = 0.002)\) | \(-0.22 (p = 0.028)\) | \(-0.16 (p = 0.105)\) |

Correlation analyses performed by Pearson’s correlation or Spearman’s correlation when data were not normally distributed.

aLBM, appendicular lean body mass.
Association between GDF15 and other inflammatory markers and clinical parameters in cancer subjects

Levels of GDF15 correlated positively with those of IL-6, IL-1Ra, IL-2, IL-4, IL-9, IL-10, IP-10, INFγ, IP-10, MCP-1, MIP-1α, MIP-1β, TNFα, VEGFA, and Activin A in patients with cancer. Also, GDF15, IL-6, IL-8, and IL-1ra levels significantly correlated with 6 month weight loss (see Supporting Information, Table S1). GDF15 negatively correlated with aLBM, handgrip strength, and FM. IL-8 and Activin A negatively correlated with aLBM and FM (Table 3). There was no association between GDF15 and appetite scores as measured by the Anderson Symptom Assessment Scale (not shown). Performance status as measured by ECOG was positively correlated with Activin A and negatively correlated with IL-2; KPS was negatively correlated with Activin A and positively correlated with IL-2; regarding FACIT-F scores, physical domain scores were negatively correlated with GDF15 (Table S2). The association between hs-CRP and albumin and other clinical parameters has been reported previously.15

Subset analyses in lung cancer subjects

Subset analyses were performed with data from patients with lung cancer, the largest group of patients available by cancer diagnosis. Sample size was too small in other tumour types to conduct these statistical analyses. In this subset, multivariate logistic regression was used to evaluate the association between the cytokine levels and C-WL after adjusting for tumour stage. GDF15, VEGFA, MIP-1β, IL-12, PDGFbb, RANTES, and IL-6 were significantly associated with weight loss in patients with lung cancer (Table 4). In order to perform a multivariate logistic regression analysis, cytokines were removed from further analyses when the Pearson correlation coefficients were greater than 0.5. Activin A, IL-6, and IL-8 were strongly correlated among themselves; RANTES, IL-8, VEGFA, and PDGFbb were also strongly correlated with each other (Table S3). Therefore, only GDF15, IL-6, PDGFbb, MIP-1β, and IL-12 were included for further analysis. Of the five cytokines subjected to multivariate logistic

Table 4 Association between weight loss and cytokines in the lung cancer patient subset (21 C-WL, 20 C-WS)

| Analyte         | Beta  | P value |
|-----------------|-------|---------|
| GDF15/C0        | −1.0685 | 0.0088 |
| VEGF/C0         | −0.5251 | 0.0105 |
| MIP-1b/C0       | −1.3202 | 0.0155 |
| IL-12/C0        | −0.3602 | 0.0157 |
| PDGFbb/C0       | −0.4887 | 0.0209 |
| RANTES/C0       | −0.6513 | 0.0240 |
| IL-6/C0         | −0.4336 | 0.0319 |
| IL-8/C0         | −0.6927 | 0.0600 |
| FGFβ/C0         | −0.5923 | 0.0648 |
| TNFα/C0         | −0.2418 | 0.0800 |
| Activin A/C0    | −0.6078 | 0.1170 |
| INFγ/C0         | −0.3372 | 0.1511 |
| IL-1Ra/C0       | −0.3811 | 0.1658 |
| IL-10/C0        | −0.2030 | 0.1917 |
| IL-4/C0         | −0.4575 | 0.1980 |
| MCP-1/C0        | −0.4698 | 0.2250 |
| IL-17/C0        | −0.1479 | 0.2475 |
| IL-7/C0         | −0.1950 | 0.2812 |
| IL-13/C0        | −0.2052 | 0.3183 |
| IL-9/C0         | −0.1237 | 0.3198 |
| GM-CSF/C0       | −0.1127 | 0.3567 |
| IL-5/C0         | −0.1584 | 0.5462 |
| Eotaxin/C0      | −0.0547 | 0.5926 |
| IL-15/C0        | 0.1127  | 0.5998 |
| MIP-1α/C0       | −0.1140 | 0.6071 |
| G-CSF/C0        | −0.0563 | 0.6540 |
| IL-2/C0         | −0.0651 | 0.7981 |
| IP-10/C0        | 0.0422  | 0.9068 |
| IL-1b/C0        | −0.0177 | 0.9529 |

Multivariate logistic regression analysis adjusting by tumour stage was used. Beta represents the association coefficient estimate.

Association between GDF15 and other inflammatory markers and clinical parameters in cancer subjects

Levels of GDF15 correlated positively with those of IL-6, IL-1Ra, IL-2, IL-4, IL-9, IL-10, IP-10, INFγ, IP-10, MCP-1, MIP-1α, MIP-1β, TNFα, VEGFA, and Activin A in patients with cancer. Also, GDF15, IL-6, IL-8, and IL-1ra levels significantly correlated with 6 month weight loss (see Supporting Information, Table S1). GDF15 negatively correlated with aLBM, handgrip strength, and FM. IL-8 and Activin A negatively correlated with aLBM and FM (Table 3). There was no association between GDF15 and appetite scores as measured by the Anderson Symptom Assessment Scale (not shown). Performance status as measured by ECOG was positively correlated with Activin A and negatively correlated with IL-2; KPS was negatively correlated with Activin A and positively correlated with IL-2; regarding FACIT-F scores, physical domain scores were negatively correlated with GDF15 (Table S2). The association between hs-CRP and albumin and other clinical parameters has been reported previously.15

Subset analyses in lung cancer subjects

Subset analyses were performed with data from patients with lung cancer, the largest group of patients available by cancer diagnosis. Sample size was too small in other tumour types to conduct these statistical analyses. In this subset, multivariate logistic regression was used to evaluate the association between the cytokine levels and C-WL after adjusting for tumour stage. GDF15, VEGFA, MIP-1β, IL-12, PDGFbb, RANTES, and IL-6 were significantly associated with weight loss in patients with lung cancer (Table 4). In order to perform a multivariate logistic regression analysis, cytokines were removed from further analyses when the Pearson correlation coefficients were greater than 0.5. Activin A, IL-6, and IL-8 were strongly correlated among themselves; RANTES, IL-8, VEGFA, and PDGFbb were also strongly correlated with each other (Table S3). Therefore, only GDF15, IL-6, PDGFbb, MIP-1β, and IL-12 were included for further analysis. Of the five cytokines subjected to multivariate logistic
regression analysis adjusted by tumour stage, GDF15 was identified as the only predictor of weight loss (Table S4).

Survival analysis

Survival analysis showed that GDF15 and IL-8 predicted survival after adjusting for stage and weight change (Cox regression $P < 0.001$ for both). Cancer diagnosis per se was not a significant predictor of survival in this model (not shown). Kaplan–Meier analysis by GDF15 and IL-8 quartiles showed that lower GDF15 and IL-8 levels were associated with better survival ($P < 0.05$ for both; Figure 2), while conversely, the highest quartile was associated with the poorest survival.

Discussion

Several lines of evidence suggest a prognostic link between weight loss and cancer. For example, weight loss and anorexia were reported to be associated with poor prognosis and worse survival in cancer and other chronic conditions in several studies.$^{17,18}$ Others have shown that both weight loss and anorexia are associated with greater mortality in patients with terminal cancer.$^{19}$ Despite the enormous burden on patients, cancer-related anorexia and weight loss are often undiagnosed and remain untreated. Also, inflammatory markers are thought to play a role in the development of these symptoms, and the prognostic value of some of these markers has been examined before.$^{20–23}$

The transforming growth factor beta family of cytokines has recently been identified as a potential therapeutic target for C-WL, given that it is one of the key regulators of lean body mass and body weight. A novel member of this family known as macrophage inhibitory cytokine-1/GDF15, originally identified as a key regulator of macrophage activation, was shown to induce anorexia and weight loss in mice bearing tumours over-expressing GDF15. Moreover, these effects were neutralized by administration of monoclonal antibodies targeting GDF15.$^{8}$

In humans, the role of GDF15 is still controversial, with some studies reporting an association with weight loss and survival in patients with prostate cancer while other studies reporting an association between GDF15 and other inflammatory markers but not with nutritional status or survival in patients with gastrointestinal tumours.$^{9,10}$ The purpose of this study was to further characterize the role of GDF15 and other inflammatory markers in humans with cancer with and without weight loss compared with non-cancer controls and to establish the association between these markers and clinically relevant outcomes including body composition, body weight, muscle strength, and overall survival.

In this study, circulating levels of GDF15 were significantly increased in patients with cancer with weight loss compared with patients with cancer without weight loss and non-cancer controls. Moreover, GDF15 levels were associated with weight loss, decreased FM, muscle mass, strength, physical performance scores, and survival in patients with cancer. This is very relevant because LBM loss is a negative and independent prognostic factor in patients with cancer$^{18}$ and decreased grip strength is associated with poor survival in this population.$^{24}$ Lean body mass in the extremities (also known as appendicular LBM or aLBM) is a good surrogate for muscle mass, given that most of the lean tissue in this area is skeletal muscle,$^{25}$ unlike the lean body mass in the trunk that includes a large amount of non-skeletal lean tissue such as liver, gastrointestinal tract, and heart. Although causality cannot be inferred from the current study, these associations between GDF15 levels, muscle mass, and strength and survival suggest that it could be used as a prognostic biomarker in this setting as others have previously proposed.$^{26}$

GDF15 has been postulated to play a role in cancer-induced weight loss by inducing anorexia in animal models; hence, it is intriguing that appetite scores were not associated with GDF15 levels in our study in spite of the clear association with other parameters that are clinically relevant such as LBM, body weight, and survival. Our study was not set up to answer this question but it is possible that the acute effect of GDF15 on appetite demonstrated in rodents is not maintained chronically or that other factors inherent to patients with cancer (i.e. administration of chemotherapy and opioids) interfere with this association. More studies will be needed to explore this issue in more depth.

The association between GDF15 and decreased aLBM, FM, and grip strength in patients with cancer suggests that this molecule may be involved in the regulation of body composition and muscle function in this setting. Although the mechanism cannot be elucidated from this study, several hypotheses could explain these findings. GDF15 has been proposed to cause anorexia through a direct effect on the hypothalamus, at least in rodents.$^{8}$ Also, other members of the transforming growth factor beta receptor superfamily such as myostatin or Activin A directly regulate muscle mass by promoting proteolysis and decreasing protein synthesis.$^{27–29}$ Whether GDF15 shares the same pathways in muscle remains to be determined and should be the focus of future studies.

In rodent models, Activin A induces weight loss and inhibition of the Activin receptor type IIb in skeletal muscle reverses the phenotype and increases survival.$^{28}$ However, data in humans of the potential role of Activin A in this setting are lacking. Here, we report that circulating levels of Activin A were increased in patients with cancer with weight loss and that it correlated with LBM, FM, and performance status scores. This is consistent with the notion that in

Journal of Cachexia, Sarcopenia and Muscle 2015; 6: 317–324
DOI: 10.1002/jcsm.12033
addition to GDF15, plasma Activin A levels may also be used as a biomarker of cachexia in humans and may serve to guide future therapeutic interventions. The association between Activin A and LBM also supports the concept that the cellular target of this pathway is skeletal muscle.

Several other pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β have been associated with cachexia and anorexia in both humans and rodents but the role of IL-8 in C-WL is less well characterized. In our cohort, IL-8 was associated not only with aLBM and FM but also with survival. To our knowledge, this is the most comprehensive characterization of the associations between IL-8 and other clinical parameters in this setting. Given that genetic polymorphisms of IL-8 have been associated with an increased risk for C-WL and that in-vitro studies have shown that IL-8 induces the synthesis of hepatic inflammatory mediators, it is tempting to think that there is a causal relationship between IL-8 induction and the aforementioned outcomes. More studies will be needed to test this hypothesis. IL-2 was not different between groups, but it correlated well with muscle proteolysis among its various outcomes. Nevertheless, these findings, GDF15 may potentially serve as a prognostic indicator in patients with cancer. GDF-15 is also being evaluated as a potential therapeutic target for the treatment of C-WL.

**Acknowledgements**

The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia, and Muscle 2010;1:7–8 (von Haehling S., Morley J. E., Coats A. J. S., Anker S. D.).

**Funding**

This study was funded by AVEO Pharmaceuticals, by the Department of Veterans Affairs (MERIT grants: I01-BX000507 and I01 CX000174) and the National Institutes of Health (AG040583). We thank the Baylor Diabetes and Endocrinology Research Center (P30 DK079638) for their help.

**Supporting information**

Supporting information may be found in the online version of this article.

**Table S1.** Correlations between inflammatory markers and 6 month body weight loss.

**Table S2.** Association between inflammatory cytokines and performance status and FACIT-F scores.

**Table S3.** Correlation coefficients among the top nine cytokines that are associated with cancer-related weight loss in lung cancer.

**Table S4.** Association between weight loss and cytokine levels using multivariate analysis, adjusting by tumor stage using logistic regression in lung cancer patients subset. Weight loss ~ Tumor stage + GDF15+Activin A+IL-6+IL-8+VEGFA.

**Conflict of interest**

L.L., N.T., B.K., B.F., R.N., and J.G. are employees of AVEO Pharmaceuticals. M.I.C. and J.W. are former employees of AVEO Pharmaceuticals. J.M.G. receives research support and is a consultant for AVEO Pharmaceuticals.
References

1. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005; 8: 265–9.

2. Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care Journal Pain Symptom Manage 1999; 17: 240–7.

3. Utchet AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. Journal Cachexia Sarcopenia Muscle 2012; 3: 245–51.

4. Batista ML Jr., McDonald ME, Alcantara PS, Olivan M, Otoch JP, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine 2012; 57: 9–16.

5. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 2002; 293: 560–5.

6. Lyngso L, Simonsen L, Bulow J. Metabolic effects of interleukin-6 in human splanchic and adipose tissue. J Physiol 2002; 543: 379–86.

7. Valenzuela SM, Martin DK, Por SB, Robbins JM, Wartan K, Bootcov MR, et al. Molecular cloning and expression of a chloride ion channel of cell nuclei. J Biol Chem 1997; 272: 12575–82.

8. Johen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 2007; 13: 1333–40.

9. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL, et al. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 2005; 11: 6658–64.

10. Skipworth RJ, Deans DA, Tan BH, Sangster K, Paterson-Brown S, Brown DA, et al. Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer 2010; 102: 665–72.

11. Death Master File [database on the Internet]. 2005 [cited 7 August 2010]. Available from: http://www.segenology.com/search/vital_ssd.htm.

12. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6–9.

13. Heedman PA, Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 2001; 21: 4077–82.

14. Cella DF, VonRoenn J, Lloyd S, Browder HP. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients’ subjective response to treatment for anorexia/cachexia. Qual Life Res 1995; 4: 211–31.

15. Burney BO, Hayes TG, Smiechowska J, Cardwell G, Papusha V, Bhargava P, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab 2012; 97: E700–9.

16. Joiner MC, Thomas RA, Grever WE, Smolinski JM, Divine GW, Konski AA, et al. Developing point of care and high-throughput biological assays for determining absorbed radiation dose. Radiat Oncol 2011; 101: 233–6.

17. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group American Journal Medicine 1989; 69: 491–7.

18. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148: 1586–91.

19. Viganò A, Donaldson N, Higginson IJ, Bruera E, Mahmud S, Suarez-Almazor M. Quality of life and survival prediction in terminal cancer patients: a multicenter study. Cancer 2004; 101: 1090–8.

20. Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005; 90: 2920–6.

21. Laviano A, Gleason JR, Meguid MM, Yang VMN mianserin and IL-1ra on meal number and in oesophago-gastric cancer. Endocrinol Metab Clin North Am 2009; 38: 441–58.

22. Lerner L, Abbott S, Bai A, Chen T, Chiu MI, Liu Q, et al. Anti-gdf15 antibodies. Google Patents, 2013.